Table 1 Key model inputs.

Survival parameters

R/S spline model with Weibull of PFS for nivolumab plus bevacizumab and chemotherapy

Gamma0 = -6.856

-7.9745 to -5.7374

–

^8,9

Gamma1 = 3.3781

2.7465 to 4.0097

–

Gamma2 = 0.3516

0.2646 to 0.4385

–

Log-logistic model of OS for nivolumab plus bevacizumab and chemotherapy

Shape = 1.553

1.357 to 1.777

–

^8,9

Scale = 32.687

28.208 to 37.878

–

Log-logistic model of PFS for bevacizumab plus chemotherapy

Shape = 2.271

2.024 to 2.549

–

^8,9

Scale = 8.267

7.504 to 9.108

–

Log-logistic model of OS for bevacizumab plus chemotherapy

Shape = 1.765

1.566 to 1.988

–

^8,9

Scale = 24.324

21.535 to 27.475

–

Cost values

Nivolumab per 1 mg

16.1

12.08 to 20.13

Gamma

Local charge

Carboplatin per 100 mg

10.7

8.03 to 13.38

Gamma

Local charge

Paclitaxel per 30 mg

7.61

5.71 to 9.52

Gamma

Local charge

Bevacizumab per 100 mg

141.59

106.19 to 176.99

Gamma

Local charge

Subsequent anti-cancer therapy per cycle

854.05

427.02 to 1282.08

Gamma

¹⁷

Supportive care per cycle

337.5

168.75 to 506.25

Gamma

¹⁷

Routine follow-up per cycle

55.6

27.8 to 83.4

Gamma

¹⁸

Terminal care

2298.86

892.71 to 6140.16

Gamma

¹⁹

SAEs in nivolumab plus bevacizumab and chemotherapy group per event

2020

1515 to 2525

Gamma

²⁰

SAEs in Bevacizumab plus chemotherapy group per event

1573

1180 to 1966

Gamma

²⁰

Utility values

PFS

0.804

0.536 to 0.883

Bate

²¹

PD

0.321

0.05 to 0.473

Beta

²¹

Disutility of SAEs

-0.28

-0.35 to -0.21

Beta

²²

Others

Probability of SAEs in nivolumab plus bevacizumab and chemotherapy group

0.762

0.711 to 0.813

Beta

⁹

Probability of SAEs in bevacizumab plus chemotherapy group

0.749

0.698 to 0.800

Beta

⁹

Proportion of patients received subsequent therapy in nivolumab plus bevacizumab and chemotherapy group

0.604

0.546 to 0.662

Beta

⁹

Proportion of patients received subsequent therapy in bevacizumab plus chemotherapy group

0.778

0.729 to 0.827

Beta

⁹

Discount rate

0.05

0 to 0.08

-

¹¹